Related Videos
Dana-Farber Cancer Institute's Nikhil C. Munshi, MD, details study looking at COVID-19 vaccine effectiveness in patients with multiple myeloma. Research presented at ASH21.
COVID-19 vaccine and blood cancer
Dr. Nikhil Munshi and colleagues reported a study demonstrating that COVID-19 vaccination offers less protection for multiple myeloma patients, reinforcing the need for these patients to use additional precautions.
Myeloma Patients Covid-19: How to Keep Myeloma Care Safe During the Pandemic
Nikhil Munshi, MD, discusses Covid-19 and Myeloma, the understanding the disease, how to make the treatments safer all while being aware of Covid-19 protocols.
Related Podcasts
FDA Approval Insights: Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma
Dr. Munshi discusses the significance of the FDA approval of ide-cel in relapsed/refractory multiple myeloma, data from the KarMMa trial, which served as the basis for the approval, and next steps for CAR T-cell therapy in the field.